Clinical Study Of DC Combined CIK Adoptive Cellular Immunotherapy In Malignant Tumors

Objective To study the clinical efficacy of Dendritic Cells (DC) combined Cytokine-induced Killer cells (CIK) adoptive cellular immunotherapy for malignant tumors.Methods Peripheral blood mononuclear cells(PBMC) were isolated from21patients with malignant tumors using Blood Cell Separator. DC were induced from the adherent cells and the CIK cells were induced form the suspension cells. DC and CIK cells were mixed in the propo-rtion of1to5in the10th day after isolation to obtain DCIK cells. Fourteen days after isolation, DCIK cells were reinfused back to patients and the residual CIK cells were also reinfused back to patients alone. After2to3course of treatment, the clinical efficacy was determined according response Evaluation Criteria In Solid Tumors (RECIST1.1), quality of life was scored according EORTC QLQ-C30(vertion3.0) and adverse reactions were recorded according Common Terminology Criteria for Adverse Events (CTCAE3.0).Results A total of21patients received and response rate was28.6%, disease control rate was66.7%. Now,5patients had died, PFS ranged form0-14months, one year survival rate was76.19%. After treatment, T cell subsets of CD3, CD4and CD8in peripheral blood had a rising trend with statistical significance as compared with before treatment. Life quality score didn’t improve significantly, but some subscale score such as:body function, fatigue, loss of appetite alleviated significantly after treatment. Adverse reactions were rather mild,3patients had fever and high temperature range form37.5to39℃,2patients had transient rash and dispear rapidly after symptomatic treatment.Conclusion DC combined CIK adoptive celluar immunotherapy is an effective treatment for ed34courses of treatment. Among them, one patients had a complete response (CR),5patients had a partial response (PR),8patients had a stable disease (SD),7patients had a stable disease (Pmalignant tumors, which can prolong the survival time and improve the life quality and possess good safety, only few patients had rather mild adverse effects.